Pharmacokinetic properties
SAD stage, SAD) stage, SAD
Plasma concentrations of ibrexafungerp were available for analysis in 60 healthy Chinese subjects (36 in the SAD stage and 24 in the MAD stage), and these 60 subjects were included in the PK analysis.After a single oral dose in the fasting state, the mean plasma concentration of ibrexafungerp generally increased with increasing dose in a dose range of 300 to 1,500 mg (Plasma ibrexafungerp concentration (Mean ± SD, log plots) time profiles after a single dose. SAD, single ascending dose.Descriptive summary of pharmacokinetic parameters of ibrexafungerp in the single ascending dose (SAD) stage (fasting)Median (minimum, maximum).Note: Parameters were shown as Geometric Mean (coefficient of variability CV %), unless otherwise noted.Abbreviations: After multiple doses of 450 mg (fasting) or 750 mg (taken with a standard meal), mean trough plasma concentrations plateaued on days 5, 6, and 7, indicating reaching a steady state (Plasma ibrexafungerp concentration (Mean ± SD, log plots)-time curve after repeated doses. MAD, multiple ascending doses.Descriptive summary of pharmacokinetic parameters of ibrexafungerp in the multiple ascending dose (MAD) stageMedian (minimum, maximum).Note: Parameters were shown as Geometric Mean (coefficient of variability CV %), unless otherwise noted.Abbreviations: 